|
US2021102183A1
|
|
Engineered cascade components and cascade complexes
|
|
WO2020176389A1
|
|
Plasmids for gene editing
|
|
CN112074279A
|
|
Humanized BCMA antibodies and BCMA-CAR-T cells
|
|
WO2020072390A1
|
|
Suicide module compositions and methods
|
|
EP3601574A1
|
|
Engineered cascade components and cascade complexes
|
|
WO2019173248A1
|
|
Engineered nucleic acid-targeting nucleic acids
|
|
WO2019152941A1
|
|
Engineered gut microbes for reduction of reactivation of detoxified drugs
|
|
US2021002609A1
|
|
Modified lymphocytes
|
|
US10227576B1
|
|
Engineered cascade components and cascade complexes
|
|
EP3526324A1
|
|
Crispr-associated (cas) protein
|
|
WO2018031950A1
|
|
Protein engineering methods
|
|
US2019055549A1
|
|
METHODS FOR USING DNA REPAIR FOR CELL ENGINEERING (as amended)
|
|
US9816093B1
|
|
Engineered nucleic acid-targeting nucleic acids
|
|
CN108473981A
|
|
The nucleic acid of engineering targeting nucleic acid
|
|
US2017114369A1
|
|
Engineered nucleic-acid targeting nucleic acids
|
|
US2017058272A1
|
|
Directed nucleic acid repair
|
|
US2016362667A1
|
|
CRISPR-Cas Compositions and Methods
|
|
AU2015308910A1
|
|
Methods for increasing Cas9-mediated engineering efficiency
|
|
US2017037432A1
|
|
Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
|
|
US2015376586A1
|
|
RNA Modification to Engineer Cas9 Activity
|
